Tag: Obatoclax

Overexpression of anti-apoptotic Bcl-2 family proteins is a hallmark of many cancers, making them an attractive target for novel therapies. The investigational anti-cancer agent Obatoclax is a BH3 mimetic designed to inhibit these pro-survival proteins. So, what is the mechanism of action of Obatoclax? Its effects are multifaceted and extend beyond simple apoptosis inhibition.

In a phase I clinical trial for extensive-stage small cell lung cancer (ES-SCLC), 96% of patients treated with a combination including Obatoclax experienced neutropenia [1.2.1]. This article explores the full spectrum of what are the side effects of the drug Obatoclax.